hydroxyindoleacetic acid has been researched along with Depressive Disorder, Major in 40 studies
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low gamma-aminobutyric acid (GABA) is implicated in both anxiety and depression pathophysiology." | 7.80 | Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid. ( Boldrini, M; Cooper, TB; Currier, D; Ellis, SP; Malone, KM; Mann, JJ; Oquendo, MA; Sullivan, G; Watson, KT; Xie, S, 2014) |
| "We investigated the association between fluvoxamine and nausea from various viewpoints." | 7.71 | Characteristics of fluvoxamine-induced nausea. ( Nakamura, J; Shinkai, K; Terao, T; Ueda, N; Yoshimura, R, 2001) |
| "Low gamma-aminobutyric acid (GABA) is implicated in both anxiety and depression pathophysiology." | 3.80 | Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid. ( Boldrini, M; Cooper, TB; Currier, D; Ellis, SP; Malone, KM; Mann, JJ; Oquendo, MA; Sullivan, G; Watson, KT; Xie, S, 2014) |
| "We investigated the association between fluvoxamine and nausea from various viewpoints." | 3.71 | Characteristics of fluvoxamine-induced nausea. ( Nakamura, J; Shinkai, K; Terao, T; Ueda, N; Yoshimura, R, 2001) |
| "Recent studies have suggested that genetic predisposition to suicidal behavior may be independent of the risk of suicide associated to mental disorders, such as affective disorders, schizophrenia, or alcohol dependence." | 2.48 | Endophenotypes as a measure of suicidality. ( Chekhonin, VP; Chistiakov, DA; Kekelidze, ZI, 2012) |
| "Current treatments for depression are characterized by a low success rate and associated with a wide variety of side effects." | 1.46 | Ziziphi spinosae lily powder suspension in the treatment of depression-like behaviors in rats. ( Huang, M; Lu, X; Wang, Y; Wei, R; Xu, J, 2017) |
| "In the search for a biomarker for major depressive disorder (MDD), we used high-performance liquid chromatography to measure amino acids and related molecules in the cerebrospinal fluid (CSF) of 52 patients with MDD (42 depressed and 10 remitted; DSM-IV) and 54 matched controls." | 1.42 | Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder. ( Hattori, K; Higuchi, T; Hori, H; Kunugi, H; Matsumura, R; Matsuo, J; Motohashi, N; Noda, T; Ogawa, S; Ohashi, Y; Ota, M; Sasayama, D; Sato, H; Teraishi, T; Yokota, Y; Yoshida, S, 2015) |
| "Major depressive disorder is a prevalent disease, and current pharmacotherapy is considered to be inadequate." | 1.38 | Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. ( Bymaster, FP; Golembiowska, K; Kowalska, M, 2012) |
| "One hundred nine bipolar, 324 major depressive disorder, and 130 healthy volunteers were genotyped for the rs4131347 (-C8347G) promoter SNP." | 1.35 | No association between a TPH2 promoter polymorphism and mood disorders or monoamine turnover. ( Brent, D; Currier, D; Galfalvy, H; Greenhill, L; Huang, YY; Mann, JJ; Murphy, L; Oquendo, M, 2008) |
| "Mirtazapine was given in a dose of 30 mg/day for 6 weeks." | 1.33 | Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients. ( Baccichet, E; Carreira, I; Lima, L; Peña, S; Urbina, M, 2005) |
| "Forty drug-free subjects with a severe major depressive disorder and forty control subjects underwent lumber puncture and psychiatric evaluation." | 1.33 | CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. ( Hou, C; Jia, F; Li, L; Liu, Y, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.50) | 18.2507 |
| 2000's | 20 (50.00) | 29.6817 |
| 2010's | 18 (45.00) | 24.3611 |
| 2020's | 1 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, L | 1 |
| Yang, P | 1 |
| Yang, C | 1 |
| Yang, D | 1 |
| Wu, X | 1 |
| Cao, T | 1 |
| Zeng, C | 1 |
| Chen, Q | 1 |
| Zhang, S | 1 |
| Zhu, Z | 1 |
| Jiao, S | 1 |
| Cai, H | 1 |
| Wang, Y | 1 |
| Huang, M | 1 |
| Lu, X | 1 |
| Wei, R | 1 |
| Xu, J | 1 |
| Pech, J | 1 |
| Forman, J | 1 |
| Kessing, LV | 1 |
| Knorr, U | 1 |
| Pompili, M | 1 |
| Lionetto, L | 1 |
| Curto, M | 1 |
| Forte, A | 1 |
| Erbuto, D | 1 |
| Montebovi, F | 1 |
| Seretti, ME | 1 |
| Berardelli, I | 1 |
| Serafini, G | 1 |
| Innamorati, M | 1 |
| Amore, M | 1 |
| Baldessarini, RJ | 1 |
| Girardi, P | 1 |
| Simmaco, M | 1 |
| Ogawa, S | 2 |
| Tsuchimine, S | 1 |
| Kunugi, H | 2 |
| Myint, AM | 1 |
| Bondy, B | 1 |
| Baghai, TC | 1 |
| Eser, D | 1 |
| Nothdurfter, C | 1 |
| Schüle, C | 1 |
| Zill, P | 1 |
| Müller, N | 1 |
| Rupprecht, R | 1 |
| Schwarz, MJ | 1 |
| Sublette, ME | 1 |
| Galfalvy, HC | 1 |
| Hibbeln, JR | 1 |
| Keilp, JG | 1 |
| Malone, KM | 3 |
| Oquendo, MA | 5 |
| Mann, JJ | 6 |
| Zhang, ZJ | 1 |
| Wang, D | 1 |
| Man, SC | 1 |
| Ng, R | 1 |
| McAlonan, GM | 1 |
| Wong, HK | 1 |
| Wong, W | 1 |
| Lee, J | 1 |
| Tan, QR | 1 |
| Watson, KT | 1 |
| Boldrini, M | 1 |
| Ellis, SP | 3 |
| Sullivan, G | 1 |
| Cooper, TB | 1 |
| Xie, S | 1 |
| Currier, D | 3 |
| Hattori, K | 1 |
| Sasayama, D | 1 |
| Yokota, Y | 1 |
| Matsumura, R | 1 |
| Matsuo, J | 1 |
| Ota, M | 1 |
| Hori, H | 1 |
| Teraishi, T | 1 |
| Yoshida, S | 1 |
| Noda, T | 1 |
| Ohashi, Y | 1 |
| Sato, H | 1 |
| Higuchi, T | 1 |
| Motohashi, N | 1 |
| Cubala, WJ | 1 |
| Landowski, J | 1 |
| Chrzanowska, A | 1 |
| Fulcher, N | 1 |
| Tran, S | 1 |
| Shams, S | 1 |
| Chatterjee, D | 1 |
| Gerlai, R | 1 |
| Anderson, GM | 1 |
| Papadopoulos, FC | 1 |
| Galfalvy, H | 2 |
| Huang, YY | 4 |
| Jokinen, J | 3 |
| Nordström, AL | 2 |
| Nordström, P | 3 |
| Pålhagen, S | 1 |
| Qi, H | 1 |
| Mårtensson, B | 1 |
| Wålinder, J | 1 |
| Granérus, AK | 1 |
| Svenningsson, P | 1 |
| Moreno, FA | 1 |
| Parkinson, D | 1 |
| Palmer, C | 1 |
| Castro, WL | 1 |
| Misiaszek, J | 1 |
| El Khoury, A | 1 |
| Mathé, AA | 2 |
| Wright, R | 1 |
| Delgado, PL | 1 |
| Laugeray, A | 1 |
| Launay, JM | 1 |
| Callebert, J | 1 |
| Surget, A | 1 |
| Belzung, C | 1 |
| Barone, PR | 1 |
| Asellus, P | 1 |
| Golembiowska, K | 1 |
| Kowalska, M | 1 |
| Bymaster, FP | 1 |
| Nagasawa, M | 1 |
| Murakami, T | 1 |
| Tomonaga, S | 1 |
| Furuse, M | 1 |
| Chistiakov, DA | 1 |
| Kekelidze, ZI | 1 |
| Chekhonin, VP | 1 |
| Nikisch, G | 1 |
| Czernik, A | 1 |
| Eap, CB | 1 |
| Jiménez-Vasquez, P | 1 |
| Brawand-Amey, M | 1 |
| Baumann, P | 1 |
| Rees, AM | 1 |
| Austin, MP | 1 |
| Parker, G | 1 |
| Miniussi, C | 1 |
| Bonato, C | 1 |
| Bignotti, S | 1 |
| Gazzoli, A | 1 |
| Gennarelli, M | 1 |
| Pasqualetti, P | 1 |
| Tura, GB | 1 |
| Ventriglia, M | 1 |
| Rossini, PM | 1 |
| Peña, S | 1 |
| Baccichet, E | 1 |
| Urbina, M | 3 |
| Carreira, I | 1 |
| Lima, L | 3 |
| Salomon, RM | 1 |
| Kennedy, JS | 1 |
| Johnson, BW | 1 |
| Urbano Blackford, J | 1 |
| Schmidt, DE | 1 |
| Kwentus, J | 1 |
| Gwirtsman, HE | 1 |
| Gouda, JF | 1 |
| Shiavi, RG | 1 |
| Bell, CJ | 1 |
| Hood, SD | 1 |
| Nutt, DJ | 1 |
| Mata, S | 2 |
| Zhou, Z | 1 |
| Roy, A | 1 |
| Lipsky, R | 1 |
| Kuchipudi, K | 1 |
| Zhu, G | 1 |
| Taubman, J | 1 |
| Enoch, MA | 1 |
| Virkkunen, M | 1 |
| Goldman, D | 2 |
| Manzano, E | 1 |
| Ortiz, T | 1 |
| Sher, L | 1 |
| Hou, C | 1 |
| Jia, F | 1 |
| Liu, Y | 1 |
| Li, L | 1 |
| Lundbäck, E | 1 |
| Forslund, K | 1 |
| Rylander, G | 1 |
| Asberg, M | 1 |
| Zalsman, G | 1 |
| Burke, AK | 1 |
| Hu, XZ | 1 |
| Brent, DA | 1 |
| Murphy, L | 1 |
| Brent, D | 1 |
| Greenhill, L | 1 |
| Oquendo, M | 1 |
| Cremniter, D | 1 |
| Jamain, S | 1 |
| Kollenbach, K | 1 |
| Alvarez, JC | 1 |
| Lecrubier, Y | 1 |
| Gilton, A | 1 |
| Jullien, P | 1 |
| Lesieur, P | 1 |
| Bonnet, F | 1 |
| Spreux-Varoquaux, O | 1 |
| Placidi, GP | 1 |
| Ueda, N | 1 |
| Yoshimura, R | 1 |
| Shinkai, K | 1 |
| Terao, T | 1 |
| Nakamura, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transcutaneous Electrical Acupoint Stimulation (TEAS) and Dense Cranial Electroacupuncture Stimulation (DCEAS) for Psychiatric Sequelae and Related Biomarkers in Women Victims of Domestic Violence: a Randomized Controlled Trial[NCT05102253] | 110 participants (Anticipated) | Interventional | 2022-07-13 | Recruiting | |||
| A Phase I Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of HS-10353 in Chinese Adult Subjects[NCT05195203] | Phase 1 | 96 participants (Actual) | Interventional | 2021-01-27 | Completed | ||
| A Randomised, Double-Blind, Placebo Controlled Trial of Omega-3 Polyunsaturated Fatty Acids as a Monotherapy for Major Depression[NCT00238758] | Phase 2 | 128 participants | Interventional | 2005-10-31 | Recruiting | ||
| A Randomised, Double-Blind, Placebo Controlled Trial of Omega-3 Polyunsaturated Fatty Acid as an Augmentor of Antidepressant Medication for Major Depression.[NCT00289484] | Phase 2 | 52 participants | Interventional | 2006-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for hydroxyindoleacetic acid and Depressive Disorder, Major
| Article | Year |
|---|---|
Poor evidence for putative abnormalities in cerebrospinal fluid neurotransmitters in patients with depression versus healthy non-psychiatric individuals: A systematic review and meta-analyses of 23 studies.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Depressive Disorder, Major; Female; gamma-Aminobutyric A | 2018 |
Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: A meta-analysis of historic evidence.
Topics: Biomarkers; Depressive Disorder, Major; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxy | 2018 |
Endophenotypes as a measure of suicidality.
Topics: Alleles; Brain; Depressive Disorder, Major; Endophenotypes; Epigenesis, Genetic; Genetic Association | 2012 |
Role of omega-3 fatty acids as a treatment for depression in the perinatal period.
Topics: Cross-Sectional Studies; Depression, Postpartum; Depressive Disorder, Major; Dose-Response Relations | 2005 |
Role of omega-3 fatty acids as a treatment for depression in the perinatal period.
Topics: Cross-Sectional Studies; Depression, Postpartum; Depressive Disorder, Major; Dose-Response Relations | 2005 |
Role of omega-3 fatty acids as a treatment for depression in the perinatal period.
Topics: Cross-Sectional Studies; Depression, Postpartum; Depressive Disorder, Major; Dose-Response Relations | 2005 |
Role of omega-3 fatty acids as a treatment for depression in the perinatal period.
Topics: Cross-Sectional Studies; Depression, Postpartum; Depressive Disorder, Major; Dose-Response Relations | 2005 |
Acute tryptophan depletion. Part II: clinical effects and implications.
Topics: Alleles; Alzheimer Disease; Autistic Disorder; Bipolar Disorder; Cognitive Behavioral Therapy; Depre | 2005 |
Alcoholism and suicidal behavior: a clinical overview.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Tricyclic; Anxiety; Comorbidity; | 2006 |
3 trials available for hydroxyindoleacetic acid and Depressive Disorder, Major
| Article | Year |
|---|---|
CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls.
Topics: Adult; Analysis of Variance; Case-Control Studies; Chromatography, High Pressure Liquid; Circadian R | 2010 |
Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression?
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Chromatography, High Pressure Liquid; Depress | 2005 |
Treatment enhances ultradian rhythms of CSF monoamine metabolites in patients with major depressive episodes.
Topics: Activity Cycles; Adult; Antidepressive Agents; Area Under Curve; Biogenic Monoamines; Depressive Dis | 2005 |
31 other studies available for hydroxyindoleacetic acid and Depressive Disorder, Major
| Article | Year |
|---|---|
Disturbance of neurotransmitter metabolism in drug-naïve, first-episode major depressive disorder: a comparative study on adult and adolescent cohorts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adult; Biomarkers; Depressive Disorder, Major; Dopamine; | 2022 |
Ziziphi spinosae lily powder suspension in the treatment of depression-like behaviors in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Depre | 2017 |
Tryptophan and Kynurenine Metabolites: Are They Related to Depression?
Topics: Adult; Bipolar Disorder; Case-Control Studies; Depressive Disorder, Major; Female; Humans; Hydroxyin | 2019 |
Tryptophan metabolism and immunogenetics in major depression: a role for interferon-γ gene.
Topics: Adult; Aged; Depressive Disorder, Major; Female; Humans; Hydroxyindoleacetic Acid; Immunogenetics; I | 2013 |
Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Fatty Acids, U | 2014 |
Platelet 5-HT(1A) receptor correlates with major depressive disorder in drug-free patients.
Topics: Adult; Analysis of Variance; Blood Platelets; Depressive Disorder, Major; Female; Humans; Hydroxyind | 2014 |
Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid.
Topics: Adult; Age Factors; Anxiety; Bipolar Disorder; Case-Control Studies; Chromatography, High Pressure L | 2014 |
Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder.
Topics: Adult; Amino Acids; Case-Control Studies; Demography; Depressive Disorder, Major; Ethanolamine; Fema | 2015 |
Salivary 5-hydroxyindole acetic acid (5-HIAA) in drug-naïve patients with short-illness-duration first episode major depressive disorder.
Topics: Adult; Case-Control Studies; Depressive Disorder, Major; Female; Humans; Hydroxyindoleacetic Acid; M | 2014 |
Neurochemical and Behavioral Responses to Unpredictable Chronic Mild Stress Following Developmental Isolation: The Zebrafish as a Model for Major Depression.
Topics: Animals; Behavior, Animal; Brain; Depressive Disorder, Major; Disease Models, Animal; Dopamine; Hydr | 2017 |
Assessing the assessment of brain serotonin turnover.
Topics: Brain; Depressive Disorder, Major; Genotype; Humans; Hydroxyindoleacetic Acid; Selective Serotonin R | 2008 |
Season as a possible confounding factor in reduced brain serotonin turnover following selective serotonin reuptake inhibitor therapy.
Topics: Brain; Depressive Disorder, Major; Genotype; Humans; Hydroxyindoleacetic Acid; Seasons; Selective Se | 2008 |
Increased risk of suicide attempt in mood disorders and TPH1 genotype.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Black or African American; Depressive Disorder, Major; Fe | 2009 |
CSF 5-HIAA and DST non-suppression--orthogonal biologic risk factors for suicide in male mood disorder inpatients.
Topics: Adult; Biomarkers; Bipolar Disorder; Cause of Death; Cohort Studies; Cross-Sectional Studies; Depres | 2009 |
Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression.
Topics: Aged; Analysis of Variance; Biogenic Monoamines; Brain-Derived Neurotrophic Factor; Corticosterone; | 2010 |
Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression.
Topics: Animals; Brain; Chronic Disease; Depressive Disorder, Major; Disease Models, Animal; Hydroxyindoleac | 2010 |
Cholesterol and CSF 5-HIAA in attempted suicide.
Topics: Adjustment Disorders; Adolescent; Adult; Age Factors; Aged; Alcoholism; Anxiety Disorders; Bipolar D | 2010 |
Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Aza Co | 2012 |
The impact of chronic imipramine treatment on amino acid concentrations in the hippocampus of mice.
Topics: Amino Acids; Animals; Antidepressive Agents, Tricyclic; Body Weight; Brain Chemistry; Cerebral Corte | 2012 |
Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response.
Topics: Adult; Chi-Square Distribution; Citalopram; Depressive Disorder, Major; Female; Homovanillic Acid; H | 2004 |
Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cell Membrane; De | 2005 |
Allelic isoforms and decrease in serotonin transporter mRNA in lymphocytes of patients with major depression.
Topics: Adult; Alleles; Biomarkers; Depressive Disorder, Major; Female; Fluorescent Antibody Technique; Huma | 2005 |
Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations.
Topics: Adult; Black or African American; Case-Control Studies; Depressive Disorder, Major; Female; Finland; | 2005 |
Noradrenaline transporter and its turnover rate are decreased in blood lymphocytes of patients with major depression.
Topics: Adult; Blood Platelets; Cell Membrane; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hydro | 2005 |
CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder.
Topics: Adult; Aged; Depressive Disorder, Major; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxyi | 2006 |
CSF 5-HIAA and the rorschach test in patients who have attempted suicide.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Female; Humans; Hydroxyindoleacetic Acid; Male; | 2006 |
Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression.
Topics: Adult; Alleles; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; F | 2006 |
No association between a TPH2 promoter polymorphism and mood disorders or monoamine turnover.
Topics: Adult; Bipolar Disorder; Child; Child Abuse; Depressive Disorder, Major; Female; Genotype; Homovanil | 2008 |
CSF 5-HIAA levels are lower in impulsive as compared to nonimpulsive violent suicide attempters and control subjects.
Topics: Adult; Aged; Anxiety Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Homovanilli | 1999 |
Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels.
Topics: Adult; Aggression; Depressive Disorder, Major; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 2001 |
Characteristics of fluvoxamine-induced nausea.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Benzamides; Depressive Disorder, Major; Dose-Response R | 2001 |